CA
PETX

Continental Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Continental Advisors’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-124,399
Closed -$786K – 151
2016
Q2 		$786K Hold
124,399
– – 0.24% 95
2016
Q1 		$687K Buy
+124,399
New +$468K 0.19% 99

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Continental Advisors's PETX Position: Q3 2016 in Review

Continental Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2016, closing a stake of 124,399 shares — an estimated $786K sold.

Continental Advisors first reported a position in PETX in Q1 2016 and held it in 2 quarters. The position peaked at $786K in Q2 2016. 128 funds tracked by Wall St. Rank hold PETX as of Q3 2016.

  • Continental Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Continental Advisors sold 124,399 Aratana Therapeutics, Inc. shares in Q3 2016, an estimated $786K.
  • Continental Advisors first reported a position in Aratana Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
  • Continental Advisors's Aratana Therapeutics, Inc. position peaked at $786K in Q2 2016.
  • 128 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2016.

Based on Continental Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.